Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Rifampin on Pevonedistat PK in Advanced Solid Tumors
NCT03486314Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevonedistat in solid tumor (advanced stage) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10), Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUClast) at Day 10 and 1 more. Started Aug 2018; status: completed.
02
Drugs
pevonedistat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03486314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486314.